Journal Mobile Options
Table of Contents
Vol. 36, No. 5, 1996
Issue release date: 1996
Eur Neurol 1996;36:288–292
Original Paper

Effects of Acyclovir on Sensory Axonal Neuropathy, Segmental Motor Paresis and Postherpetic Neuralgia in Herpes zoster Patients

Mondelli M.a,d · Romano C.b · Passero S.c · Della Porta P.a · Rossi A.a
Institutes of aNeurological Sciences, bDermatology, and cNervous and Mental Diseases, University of Siena, and dEMG Service, USL 7, Siena, Italy


The effect of oral treatment with acyclovir (ACV) on sensory axonal neuropathy, segmental motor paresis and postherpetic neuralgia (PHN) was studied in 105 patients with herpes zoster. Forty-seven patients were treated with ACV at a dose of 4 g/day in 5 doses for at least a week; the others did not undergo any kind of treatment. Electrodiagnostic examination of the nerves and muscles corresponding to the dermatomeric lesions was performed, including sensory and motor nerve conduction studies, blink reflex and electromyography (EMG). The patients treated with ACV showed a significant reduction in the number of cases in which there was electrophysiological evidence of axonal damage in afferent fibres of nerves arising from roots corresponding to affected dermatomes. The treated group also showed a smaller incidence of segmental motor neuritis, clinically evident or only detectable by EMG as denervation. However, there was no significant difference between groups as far as the incidence of PHN was concerned. Oral treatment with ACV therefore reduces peripheral sensory axonopathy due to ganglion damage and prevents the possibility of spread to anterior roots and spinal motoneurones. In this way it reduces the incidence of segmental motor neuritis, but does not reduce the incidence of PHN.

 goto top of outline Author Contacts

M. Mondelli, MD, Istituto di Scienze Neurologiche, Università di Siena, Viale Bracci, I-53100 Siena (Italy)

 goto top of outline Article Information

Received: October 2, 1995
Accepted: February 9, 1996
Published online: February 13, 2008
Number of Print Pages : 5

 goto top of outline Publication Details

European Neurology

Vol. 36, No. 5, Year 1996 (Cover Date: 1996)

Journal Editor: Bogousslavsky, J. (Montreux)
ISSN: 0014–3022 (Print), eISSN: 1421–9913 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.